6 completed, 2 withdrawn, 1 unknown. 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Withdrawn 2, Unknown 1 |
Follow peginterferon lambda-1a: new trials by email Literature Review of peginterferon lambda-1a trials Research Report on peginterferon lambda-1a
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis Peginterferon Lambda - Chronic Hepatitis Delta | Phase 2 | Withdrawn | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2024-05-22 | 2024-05-23 | |
| Interferon Lambda Therapy for COVID-19 Peginterferon Lambda-1A - SARS-CoV-2 | Phase 2 | Withdrawn | Icahn School of Medicine at Mount Sinai | 2020-09-01 | 2021-02-26 | |
| Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19 Peginterferon Lambda-1A, placebo - Sars-CoV2, Covid-19 | Phase 2 | Completed | University Health Network, Toronto | 157 | 2020-05-13 | 2023-12-13 |
| Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19 Peginterferon Lambda-1a, Placebo - COVID-19 | Phase 2 | Completed | Stanford University | 120 | 2020-04-25 | 2021-11-30 |
| A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection Peginterferon Lambda-1A - Hepatitis D, Chronic | Phase 2 | Completed | EIT Pharma, Inc. | 33 | 2016-10-19 | 2026-09-08 |
| Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin Pegylated Interferon Lambda, Ribasphere, Daclatasvir - Hepatitis C | Phase 2 | Completed | Bristol-Myers Squibb | 165 | 2013-03-01 | 2015-10-09 |
| Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin Pegylated Interferon Lambda (pegIFNλ), BMS-790052 (NS5A Inhibitor), Ribavirin (RBV) - Hepatitis C | Phase 2 | Completed | Bristol-Myers Squibb | 165 | 2011-03-01 | 2015-10-09 |
| Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen pegIFN, pegIFNα-2a, PegIFN lambda - Hepatitis B Virus | Phase 2 | Completed | Bristol-Myers Squibb | 197 | 2010-11-01 | 2015-10-09 |
| Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection PEG-rIL-29, Peginterferon alfa-2a, Ribavirin - Hepatitis C, Chronic | Phase 2 | Unknown | ZymoGenetics | 600 | 2010-05-01 | 2011-12-05 |
Hepatitis C (3) · COVID-19 (2) · Hepatitis D, Chronic (2) · Coronavirus Infections (1) · Hepatitis B (1) · Hepatitis C, Chronic (1) · Hepatitis D (1) · Infections (1) · Liver Diseases (1) · Virus Diseases (1)
Bristol-Myers Squibb (3) · EIT Pharma, Inc. (1) · Icahn School of Medicine at Mount Sinai (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Stanford University (1) · University Health Network, Toronto (1) · ZymoGenetics (1)
United States (6) · Australia (3) · Canada (3) · France (3) · Germany (3) · Italy (3) · New Zealand (2) · Puerto Rico (2) · Spain (2) · Austria (1) · Brazil (1) · Hong Kong (1) · Israel (1) · Japan (1) · Netherlands (1)
Christopher Koh, M.D. (1) · David Apelian, MD, PhD, MBA (1) · Jan Hillson, MD (1) · Jordan Feld, MD (1) · Thomas Marron, MD (1) · Upinder Singh (1)
PMID 32788708, PMID 25042797, PMID 25043197, PMID 26739688, PMID 28611778, PMID 32555385, PMID 33556319, PMID 33624010, PMID 33785743, PMID 35588734, PMID 37147857
2009 (1)